Status:
COMPLETED
The Development of a Mobile-based App to Increase Uptake of Pre-Exposure Prophylaxis (PrEP) by Men Who Have Sex With Men in China
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborating Sponsors:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
HIV
Pre-exposure Prophylaxis
Eligibility:
MALE
18-99 years
Phase:
NA
Brief Summary
This study aims to use a mini-application on the popular Chinese social media mobile platform, WeChat, to improve HIV pre-exposure prophylaxis (PrEP) uptake among at-risk men who have sex with men (MS...
Detailed Description
This study includes two parts. Before the start of Part 1, a mini-app prototype for promoting HIV pre-exposure prophylaxis (PrEP) uptake will have been developed from a prior MSM community-driven hack...
Eligibility Criteria
Inclusion
- Part 1: HIV-negative men who have sex with men (MSM): must self-report: being assigned male sex at birth, HIV-negative, age 18 and above, ever having had anal sex with another man, identify as a Chinese citizen, own a smartphone, able to being willing to sign written informed consent and participate in the study as procedures required.
- Part 2: HIV-negative men who have sex with men (MSM): same characteristics as in Part 1.
- AND, they must report :
- Having a smartphone with WeChat installed.
- Being assigned male sex at birth, HIV-negative, age 18 and above, ever having had anal sex with another man, currently reside in Guangzhou, China, identifying as a Chinese citizen, able to sign written informed consent and participate in the study as procedures require. AND
- At least one criterion associated with high risk of HIV infection in the past 6 months prior to enrollment as follows:
- Unprotected (condomless) anal intercourse with male partner(s)
- More than two male partners (regardless of condom use and HIV serostatus)
- Reported STI, such as syphilis, Herpes Simplex Virus-2 (HSV-2), gonorrhea, chlamydia, chancroid, or lymphogranuloma venereum.
- Reported use of post-exposure prophylaxis (PEP)
- Have a sexual partner living with HIV
Exclusion
- Part 1: Individuals who report any following status will be excluded from participating Part 1:
- HIV-positive
- Mental health issues which may compromise participant adherence or safety, including memory loss, cognitive impairment, intellectual disability, or communication disorders.
- Part 2:
- HIV-positive (self-report or lab-confirmed)
- Currently taking oral PrEP based on self-report
- Symptoms of acute HIV infection within the prior 30 days
- Contradictions to taking oral PrEP
- Personal diagnosis or family history of hemophilia
- Chronic Hepatitis B (self-report)
- Participating in another research study related to HIV and antiretroviral therapy or other intervention study
- Having serious chronic disease, including metabolic diseases (such as diabetes), neurological, and psychiatric disorders
- Mental health issues which may compromise participant adherence or safety, including memory loss, cognitive impairment, intellectual disability, or communication disorders
Key Trial Info
Start Date :
July 8 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 2 2021
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT04426656
Start Date
July 8 2020
End Date
April 2 2021
Last Update
March 2 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guangzhou No. 8 People's Hospital
Guangzhou, China